Pfizer expects vaccine profits up to 15 billion by 2030
2022.12.12 14:24
Pfizer expects vaccine profits up to 15 billion by 2030
Budrigannews.com – The pharmaceutical company Pfizer Inc. said on Monday that by 2030, its mRNA vaccine business’s global annual revenue could reach $10 billion to $15 billion.
In a presentation to investors, the company detailed the potential revenue it could make from all of its vaccines, including its COVID-19 vaccine, which has already been approved, and vaccines for the flu and shingles that are in development.
More Japan, US, Netherlands united against China
According to Pfizer, sales of its RSV vaccine candidate, which it expects to launch in 2023, could reach more than $2 billion in 2027.
Sales of the COVID-19 vaccine and the oral treatment Paxlovid are expected to boost the company’s revenue to more than $100 billion this year, more than double the level it had before the pandemic.
However, COVID-related sales are expected to fall sharply in the coming years, and Pfizer may lose patent protection for some of its most popular medicines after 2025, such as Ibrance for cancer and Xeljanz for arthritis.
